Literature DB >> 2025274

Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs.

S Eriksson1, B Kierdaszuk, B Munch-Petersen, B Oberg, N G Johansson.   

Abstract

Deoxynucleoside kinases are required for the 5'-phosphorylation of deoxynucleoside analogs used in chemotherapy. Cytoplasmic thymidine kinase (TK1), deoxycytidine kinase (dCK) and mitochondrial thymidine kinase (TK2) were completely purified from human leukemic spleen and their capacities to phosphorylate 43 nucleoside analogs were compared. TK1 showed the most restricted substrate specificity but tolerated 3'-modifications of the sugar ring and some 5-substitutions of the pyrimidine ring. TK2 showed a much broader specificity and phosphorylated pyrimidine bases with bulky 5-substitutions, including cytosine analogs, while sugar analogs with substituents other than OH in the 2' and 3' positions were very poor substrates. dCK showed a very broad specificity phosphorylating several cytosine analogs with 2' and 3' modifications as well as acyclic sugar analogs. Purine deoxyribonucleosides were also efficiently phosphorylated by dCK but in this case sugar modifications led to drastically decreased activity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2025274     DOI: 10.1016/s0006-291x(05)80224-4

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  37 in total

1.  Novel ribofuranosylnucleoside lead compounds for potent and selective inhibitors of mitochondrial thymidine kinase-2.

Authors:  J Balzarini; C Zhu; E De Clercq ; M J Pérez-Pérez; C Chamorro; M J Camarasa; A Karlsson
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

2.  Structural and kinetic characterization of human deoxycytidine kinase variants able to phosphorylate 5-substituted deoxycytidine and thymidine analogues .

Authors:  Saugata Hazra; Stephan Ort; Manfred Konrad; Arnon Lavie
Journal:  Biochemistry       Date:  2010-08-10       Impact factor: 3.162

3.  Cloning and expression of human deoxyguanosine kinase cDNA.

Authors:  M Johansson; A Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

4.  Inhibition of replication of hepatitis B virus by cytallene in vitro.

Authors:  Y L Zhu; S B Pai; S H Liu; K L Grove; B C Jones; C Simons; J Zemlicka; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 5.  [18F]FLT-PET in oncology: current status and opportunities.

Authors:  Lukas B Been; Albert J H Suurmeijer; David C P Cobben; Pieter L Jager; Harald J Hoekstra; Philip H Elsinga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12       Impact factor: 9.236

6.  Structures of thymidine kinase 1 of human and mycoplasmic origin.

Authors:  Martin Welin; Urszula Kosinska; Nils-Egil Mikkelsen; Cecilia Carnrot; Chunying Zhu; Liya Wang; Staffan Eriksson; Birgitte Munch-Petersen; Hans Eklund
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-20       Impact factor: 11.205

7.  Metabolism of deoxypyrimidines and deoxypyrimidine antiviral analogs in isolated brain mitochondria.

Authors:  Kathleen A McCann; David W Williams; Edward E McKee
Journal:  J Neurochem       Date:  2012-05-21       Impact factor: 5.372

8.  Exploiting temperature-dependent substrate promiscuity for nucleoside analogue activation by thymidine kinase from Thermotoga maritima.

Authors:  Stefan Lutz; Joseph Lichter; Lingfeng Liu
Journal:  J Am Chem Soc       Date:  2007-06-26       Impact factor: 15.419

9.  In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene.

Authors:  A P Stegmann; M W Honders; A Hagemeijer; B Hoebee; R Willemze; J E Landegent
Journal:  Ann Hematol       Date:  1995-07       Impact factor: 3.673

Review 10.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.